2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, PMCID: PMC12138910, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatment
2022
Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States
Harris L, L’Italien G, Kumar A, Seelam P, LaVallee C, Coric V, Lipton R. Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States. Headache The Journal Of Head And Face Pain 2022, 62: 473-481. PMID: 35343590, PMCID: PMC9313575, DOI: 10.1111/head.14289.Peer-Reviewed Original ResearchConceptsMigraine-related disabilityDirect medical costsMedical costsIVB patientsEpisodic migrainePharmacy costsGrade IMigraine Disability Assessment Scale (MIDAS) questionnaireMigraine Disability Assessment ScoreHealthcare resource utilizationMigraine Disability AssessmentPrimary care settingElectronic health record dataSubstantial economic burdenHigher medical costsHealth record dataPublic health concernCost-effective treatmentRevision 9Cohort studyHealthcare visitsMIDAS scoreMigraine disabilitySpecialty careReal-world assessmentCost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican SocietyPreliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
Buono FD, Gleed C, Boldin M, Aviles A, Wheeler N. Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial. JMIR Research Protocols 2022, 11: e30186. PMID: 35029534, PMCID: PMC8800086, DOI: 10.2196/30186.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERAlcohol use disorderQuality of lifeBlood alcohol concentrationUse disordersAlcohol use disorder populationTreatment providersPsychological distressRandomized clinical trialsLong-term treatmentTreatment motivationCost-effective treatmentControlled TrialsDisease management approachTreatment modalitiesChronic disordersAlcohol concentrationClinical trialsDropout ratePreliminary effectivenessAlcohol dependenceTimely interventionDisorder populationMonthsHigher likelihood
2021
Emergency Department Treatment of Opioid Use Disorder
Samuels E, Coupet E, D’Onofrio G. Emergency Department Treatment of Opioid Use Disorder. 2021, 57-75. DOI: 10.1007/978-3-030-80818-1_5.ChaptersOpioid use disorderED visitsUse disordersUntreated opioid use disorderDrug-related emergency department visitsNonfatal opioid overdoseUS ED visitsEmergency department treatmentFirst-line treatmentLow-dose ketamineEmergency department visitsIllicit opioid useDosage of medicationRegional nerve blocksAddiction treatment medicationsHarm reduction servicesTake-home naloxoneCost-effective treatmentAcute painOpioid useDepartment visitsOUD treatmentTreatment medicationsNerve blockOpioid agonistsDesign and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Ul Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz CS, Parise H, Lansky A. Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. Contemporary Clinical Trials 2021, 110: 106547. PMID: 34461322, PMCID: PMC8397504, DOI: 10.1016/j.cct.2021.106547.Peer-Reviewed Original ResearchConceptsHospitalized COVID-19 patientsCOVID-19 patientsStandard of careElectronic health recordsComplications TrialSevere COVID-19 diseaseWorld Health Organization (WHO) ordinal scaleVenous thromboembolic eventsHealth recordsCombination of colchicineRates of morbidityCOVID-19 diseaseCost-effective treatmentPrimary endpointRespiratory failureThromboembolic eventsClinical improvementMyocardial injuryPragmatic trialClinical trialsPatientsEvent ascertainmentHealth NetworkRosuvastatinTrialsCost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open 2021, 4: e2033787. PMID: 33439266, PMCID: PMC7807293, DOI: 10.1001/jamanetworkopen.2020.33787.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic hormone-sensitive prostate cancerProstate radiation therapyEconomic evaluationProstate cancerHealth-state utility estimatesIncremental cost-effectiveness ratioRadiation therapyLow-volume metastatic hormone-sensitive prostate cancerProbabilistic sensitivity analysesLow burden metastatic prostate cancerLow-volume metastatic prostate cancerCost-effectiveness ratioHormone-sensitive prostate cancerDominant treatment strategyBase case scenarioFailure-free survivalUS dollarsNet costUtility estimatesDominant strategyCost-effective treatmentHigher QALYsQALYDeprivation therapy
2018
Ascites
Garcia‐Tsao G. Ascites. 2018, 127-150. DOI: 10.1002/9781119237662.ch9.Peer-Reviewed Educational MaterialsLarge-volume paracentesesHepatorenal syndromeRefractory ascitesCirrhotic ascitesCommon decompensating eventMassive hepatic metastasesPlasma renin activitySecond-line treatmentFormation of ascitesDevelopment of ascitesCost-effective treatmentSinusoidal hypertensionCardiac indexRenin activityVasodilatory stateHepatic metastasesMalignant ascitesAscites formationCommon precipitantsAscitesHigh mortalityBacterial infectionsHyponatremiaMain predictorsPatients
2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAntibodies, Monoclonal, HumanizedCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injectionCost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms
Hogendoorn W, Lavida A, Hunink MG, Moll FL, Geroulakos G, Muhs BE, Sumpio BE. Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms. Journal Of Vascular Surgery 2015, 61: 1432-1440. PMID: 25827968, DOI: 10.1016/j.jvs.2014.12.064.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAneurysmBlood Vessel Prosthesis ImplantationCost-Benefit AnalysisDecision Support TechniquesDecision TreesEndovascular ProceduresFemaleHealth Care CostsHumansMaleMarkov ChainsMiddle AgedModels, EconomicPatient SelectionPostoperative ComplicationsQuality of LifeRisk AssessmentRisk FactorsSex FactorsSoftwareSplenic ArteryTime FactorsTreatment OutcomeConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioHigher quality-adjusted life yearsReference case analysisProbabilistic sensitivity analysesCost-effectiveness ratioHealth care perspectiveExtensive sensitivity analysisSensitivity analysisDecision analysis modelLife yearsCost-effective treatmentSplenic artery aneurysmHypothetical cohortPerfect healthEndovascular repairConservative managementSmall gainsCostCare perspectiveFemale patientsAnalysis modelElderly patientsOpen repairArtery aneurysm
2007
The cost‐effectiveness of four treatments for marijuana dependence
Olmstead TA, Sindelar JL, Easton CJ, Carroll KM. The cost‐effectiveness of four treatments for marijuana dependence. Addiction 2007, 102: 1443-1453. PMID: 17645430, PMCID: PMC2398724, DOI: 10.1111/j.1360-0443.2007.01909.x.Peer-Reviewed Original ResearchConceptsMET/CBTDrug counselingContingency managementPatient outcomesYoung adultsEffective treatmentMarijuana dependenceAcceptability curvesIncremental cost-effectiveness ratioRandomized clinical trialsCost of therapyPatient outcome measuresCost-effective dependsCost-effectiveness ratioSubstance abuse clinicsCost-effective treatmentCM procedureClinical trialsOutcome measuresUrine specimenUrine specimensAdditional weeksAdditional studiesMarijuana abstinenceLonger duration
1992
Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction
Krumholz H, Pasternak R, Weinstein M, Friesinger G, Ridker P, Tosteson A, Goldman L. Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction. New England Journal Of Medicine 1992, 327: 7-13. PMID: 1598117, DOI: 10.1056/nejm199207023270102.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyRisk of deathMyocardial infarctionElderly patientsPatients 75 yearsST-segment elevationOnset of symptomsUse of streptokinaseOne-way sensitivity analysesDecision analytic modelYears of lifeCost-effective treatmentRelative reductionHospital deathStreptokinase therapyOlder patientsClinical circumstancesThrombolytic agentsInfarctionPatientsCost effectivenessTherapyLack of consensusStreptokinase
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply